Patents Examined by Alvin E. Tanenholtz
  • Patent number: 4954437
    Abstract: A rodent epithelioid cell transformed with a recombinant DNA vector including a DNA sequence encoding human erythropoietin, the transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.
    Type: Grant
    Filed: September 15, 1986
    Date of Patent: September 4, 1990
    Assignee: Integrated Genetics, Inc.
    Inventors: Anton K. Beck, Raymond M. Withy, James R. Zabrecky, Nicholas C. Masiello
  • Patent number: 4933280
    Abstract: The complete coding sequences and amino acid sequences for both canine and human 32K alveolar surfactant proteins (ASP) are disclosed; clones for the 10K protein have also been obtained. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.
    Type: Grant
    Filed: April 30, 1986
    Date of Patent: June 12, 1990
    Assignee: California Biotechnology Inc.
    Inventors: James W. Schilling, Jr., Robert T. White, Barbara Cordell, Bradley J. Benson
  • Patent number: 4912038
    Abstract: The complete coding sequences and amino acid sequences for both canine and human 32K alveolar surfactant proteins (ASP) are disclosed; clones for the 10K protein have also been obtained. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.
    Type: Grant
    Filed: December 13, 1985
    Date of Patent: March 27, 1990
    Assignee: California Biotechnology Inc.
    Inventors: James W. Schilling, Jr., Robert T. White, Barbara Cordell, Bradley J. Benson
  • Patent number: 4898830
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: February 6, 1990
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4889803
    Abstract: Interferon .gamma. is produced in highly purified form (activity exceeding 10.sup.8 units/ml-day) by CHO cells cotransformed by a first plasmid bearing the genomic human interferon gene under the control of the SV40 early promoter, and a second plasmid bearing a DHFR gene under similar control. Methotrexate selection yielded a clone which was a particularly efficient producer. Production of interferon .gamma. may also be facilitated by a Harvey sarcoma virus enhancer sequence.
    Type: Grant
    Filed: April 26, 1985
    Date of Patent: December 26, 1989
    Assignee: Yeda Research & Development Co., Ltd.
    Inventors: Michel Revel, Menachem Rubinstein, Yvez Mory
  • Patent number: 4888280
    Abstract: Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids' .beta.-glucuronidase (BG) gene DNZ and the desired protein gene DNA. Specifically exemplified are plasmids which comprise BG gene DNA and protein A DNA. E. coli K-12 derivative hosts transformed with plasmid pBG3-2.DELTA.n express >60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention.
    Type: Grant
    Filed: August 25, 1986
    Date of Patent: December 19, 1989
    Assignee: Repligen Corporation
    Inventors: John L. Palmer, Algis Anilionis
  • Patent number: 4883761
    Abstract: The complete nucleotide sequence of the pertussis toxin gene and the deduced amino acid sequences of the individual subunits have been determined. All five subunits are coded by closely linked cistrons and possibly expressed through a polycistronic mRNA, since a promotor-like structure was found in the 5' flanking region. The order of the cistrons is S1, S2, S3, S4, S5, and S3. All subunits contain signal peptides of variable length. The calculated molecular weights of the mature subunits are 25,024 for S1, 21,924 for S2, 21,873 for S3, 12,058 for S4 and 11,013 for S5. All subunits contain signal peptides of variable length. Subunits S2 and S3 share 70% amino acid homology and 75% nucleotide homology. Subunit S1 contains two regions of eight amino acids homologous to analogous regions in the A subunit of both cholera and E. coli heat labile toxins. Functional domains in relation to the primary structure and the development of a safer, new generation vaccine against whooping cough are presented.
    Type: Grant
    Filed: March 25, 1986
    Date of Patent: November 28, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jerry M. Keith, Camille Locht
  • Patent number: 4879227
    Abstract: A process for producing a novel protein, CSF-69, is provided. The protein is capable of stimulating proliferation of monocytic lineage types cells in vitro assays. A novel DNA sequence codes on expression for CSF-69.
    Type: Grant
    Filed: May 6, 1986
    Date of Patent: November 7, 1989
    Assignee: Genetics Institute, Inc.
    Inventors: Steven C. Clark, Gordon G. Wong
  • Patent number: 4877729
    Abstract: A novel family of primate IL-3-like polypeptides is provided via recombinant techniques.
    Type: Grant
    Filed: October 7, 1986
    Date of Patent: October 31, 1989
    Assignee: Genetics Institute, Inc.
    Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang
  • Patent number: 4877864
    Abstract: Human and bovine bone inductive factors are provided. Such factors may be produced by recombinant techniques and be useful in the treatment of bone defects.
    Type: Grant
    Filed: March 26, 1987
    Date of Patent: October 31, 1989
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki Rosen
  • Patent number: 4873191
    Abstract: Genetic transformation of a zygote and the embryo and mature organism which result therefrom is obtained by placing or inserting exogenous genetic material into the nucleus of the zygote or into any genetic material which ultimately forms at least a part of the nucleus of the zygote. It is preferred that the exogenous genetic material be added to a pronuclei of the zygote and is particularly preferred that it be added to the male pronucleus of the zygote. Thereafter, the zygote is allowed to undergo differentiation and development into the organism. The genotype of the zygote and the organism which results therefrom will include the genotype of the exogenous genetic material and the exogenous genetic material will be phenotypically expressed.The invention can be utilized in a variety of ways including, for example, animal and plant breeding to modify or create new species, it can be used in epigenetics and in the understanding and treatment of genetic diseases.
    Type: Grant
    Filed: August 18, 1986
    Date of Patent: October 10, 1989
    Assignee: Ohio University
    Inventors: Thomas E. Wagner, Peter C. Hoppe
  • Patent number: 4871670
    Abstract: Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.
    Type: Grant
    Filed: May 12, 1986
    Date of Patent: October 3, 1989
    Assignee: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Peter J. Hudson, John Shine, Hugh D. Niall, Geoffrey W. Tregear
  • Patent number: 4870009
    Abstract: Mammalian genes that encode hormones are cloned and linked to strong promoter DNA sequences. The linked sequences are inserted in plasmids for amplification in prokaryotic cells, and multiple copies of the linked sequences are excised therefrom. Linked sequences are subsequently microinjected into fertilized eggs and the fertilized eggs are implanted into pseudo-pregnent females of the same species. As a result, transgenic animals are born having the linked sequences incorporated into their genomes and expressing the gene-encoded hormone. Because multiple copies of the linked sequences are frequently inserted and because production of the hormone is not limited to certain organs, as is the case with most endogenous hormones, the transgenic animals produce substantial amounts of the hormone. Hormone can be harvested from the living animal (and from its hormone-producing progeny) by extracting fluid, such as blood serum or ascites fluid, on a regular basis.
    Type: Grant
    Filed: December 15, 1983
    Date of Patent: September 26, 1989
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Richard D. Palmiter, Ralph L. Brinster
  • Patent number: 4870015
    Abstract: Methods and compositions for the construction of a recombinant vector containing plant or animal lectin DNA sequences, such vector being capable of being replicated, transcribed and translated in single cell hosts. The gene coding for the plant or animal lectin may be inserted into an expression vector which enables efficient production of the lectin protein.
    Type: Grant
    Filed: March 26, 1986
    Date of Patent: September 26, 1989
    Assignee: Lubrizol Genetics, Inc.
    Inventor: Leslie M. Hoffman
  • Patent number: 4870008
    Abstract: Methods and compositions are provided for producing polypeptide sequences in high yield by employing DNA constructs, wherein the DNA sequence encoding from the polypeptide of interest in preceded by a leader sequence and processing sequence for secreting and processing said polypeptide. In this manner, the mature polypeptide of interest may be isolated from the nutrient medium substantially free of major amounts of other proteins and cellular debris.The yeast strain S. cerevisiae AB103 (pYEGF8) was deposited on Jan. 5 , 1983, at the A.T.C.C. and given accession No. 20658.The plasmid pY.alpha.EGF23 (pAB114-pCl/1) was deposited at the A.T.C.C. on Aug. 12, 1983, and given Accession No. 40079.
    Type: Grant
    Filed: August 3, 1987
    Date of Patent: September 26, 1989
    Assignee: Chiron Corporation
    Inventor: Anthony J. Brake
  • Patent number: 4868125
    Abstract: Disclosed is a novel promoter wherein a 5' flanking region of a promoter (referred to as promoter A hereinafter) is replaced with a 5' flanking region of another promoter (referred to as promoter B hereinafter) or a chemically synthesized DNA fragment. The promoter is constructed by replacing a region existing upstream from the "-35" region of promoter A with the "-35" region of promoter B or a chemically synthesized DNA fragment.
    Type: Grant
    Filed: October 28, 1987
    Date of Patent: September 19, 1989
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Tatsunari Nishi, Akiko Saito, Seiga Itoh
  • Patent number: 4868119
    Abstract: A novel family of primate CSF-1-like polypeptides is provided via recombinant techniques.
    Type: Grant
    Filed: December 11, 1986
    Date of Patent: September 19, 1989
    Assignee: Genetics Institute, Inc.
    Inventors: Steven C. Clark, Gordon G. Wong
  • Patent number: 4868113
    Abstract: Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-line structures.
    Type: Grant
    Filed: March 3, 1986
    Date of Patent: September 19, 1989
    Assignee: Rorer Biotechnology, Inc.
    Inventors: Michael Jaye, Wilson Burgess, Thomas Maciag, William Drohan
  • Patent number: 4865989
    Abstract: Novel compositions and methods employing the compositions are provided involving eukaryotic plasmids having a replication system or replicon from an extrachromosomal element, a chromosomal replicator, and the regulatory signals of the structural gene for yeast 3-phosphoglycerokinase controlling expression of a structural gene. The plasmids find particular use in yeast for production of poly(amino acids).
    Type: Grant
    Filed: October 20, 1987
    Date of Patent: September 12, 1989
    Assignee: U.C. Regents
    Inventors: Ronald Hitzeman, John A. Carbon
  • Patent number: 4865982
    Abstract: A DNA fragment from Streptomyces sp. which contains the XP55 gene expression unit.
    Type: Grant
    Filed: May 29, 1985
    Date of Patent: September 12, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: William V. Burnett, Jr., Thomas G. Eckhardt, Louis R. Fare